Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.
By M. Goetz, J. Rae, V. Suman, Stephanie L. Safgren, M. Ames, D. Visscher, C. Reynolds, F. Couch, W. Lingle, D. Flockhart and 3 more. Journal of Clinical Oncology, 2005
789 citations recorded by the source corpus.
Subfields: Genetics, Pharmacology
View Paper: https://www.semanticscholar.org/paper/0fd57e0867e4cda8159cab4ac4647a145b5082c1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Pharmacology
Citations in the corpus
- Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. (2007, background): “…homozygous for the defective allele CYP2D6⁎4 have been shown to have a worsened relapse-free time and disease-free survival rate, in addition to not experiencing hot flashes at the same magnitude as compared with women heterozygous or homozygous for the wild-type allele (Goetz et al., 2005, 2006).”
- Polymorphism of human cytochrome P450 enzymes and its clinical impact (2009, background): “…*41 associated with impaired formation of antiestrogenic metabolites had significantly more recurrences of breast cancer and shorter relapse-free periods (Bijl et al., 2009a; Bonanni et al., 2006; Borges et al., 2006; Goetz et al., 2007; Goetz et al., 2005; Jin et al., 2005; Schroth et al., 2007).”
- Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine (2016, background): “In tamoxifen-treated surgically resected ERpositive breast cancer patients, a much lower (0) prevalence of moderate to severe hot flashes, together with a higher risk of disease relapse, was reported in women with the CYP2D6*4/*4 genotype than in patients with one or no CYP2D6*4 alleles (20%) [54].”